The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 04, 2022

Filed:

Jan. 25, 2019
Applicant:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Inventors:

Dirk Block, Bichl, DE;

Hanspeter Brunner, Muenchenstein, CH;

Thomas Dieterle, Freiburg, DE;

Ursula-Henrike Wienhues-Thelen, Krailling, DE;

Christian Zaugg, Rheinfelden, CH;

Andre Ziegler, Laeufelfingen, CH;

Assignee:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/543 (2006.01); G01N 33/68 (2006.01); A61K 31/40 (2006.01); G01N 33/62 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); A61K 31/40 (2013.01); G01N 33/62 (2013.01); G01N 33/6869 (2013.01); G01N 33/6872 (2013.01); G01N 2333/47 (2013.01); G01N 2333/475 (2013.01); G01N 2333/495 (2013.01); G01N 2333/5412 (2013.01); G01N 2800/325 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.


Find Patent Forward Citations

Loading…